Sanofi Genzyme is launching a Phase 3 clinical trial testing Cerdelga (eliglustat) with or without Cerezyme (imiglucerase) in children and adolescents with Gaucher disease (GD) types 1 and 3. The multicenter, open-label ELIKIDS study (NCT03485677) will test the safety and effectiveness of Cerdelga, either alone or in combination…
News
A Lysosomal Storage Disease Research Program at Massachusetts General Hospital is conducting a survey as part of a study to investigate how those patients perceive their treatment. The survey asks for patients’ opinions on enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) and is anonymous. Titled, “Factors influencing…
A woman with type 1 Gaucher disease had several potentially light-threatening blood vessel bulges called aneurysms in her brain, according to a case study. It prompted researchers to wonder about a possible connection between the two conditions. They were unable to draw conclusions about a potential link, however.
The Parkinson’s Progression Markers Initiative (PPMI) is recruiting people with Gaucher disease for a new study in Parkinson’s disease because mutations in the GBA gene may cause both diseases. Both the National Gaucher Foundation and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) support the…
Keeping tabs on Gaucher patients’ blood glucosylsphingosine (GlcSph) levels could be an alternate way to keep track of how well treatments are working, a Polish study suggests. The research, “Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease…
Enzyme replacement therapy with Cerezyme (imiglucerase) shows long-term benefits on the quality of life in young children with Gaucher disease type 1 (GD1), a study published in Molecular Genetics & Genomic Medicine found. GD1, the most common form of the disease, is characterized by an accumulation of glucocerebroside in…
Late diagnosis and treatment of Gaucher’s disease, particularly when there are bone symptoms, can worsen a patient’s health and quality of life, a case study shows. It involved a Turkish woman whom doctors mistakenly diagnosed with brittle bone disease. The report, “Actual reason for bone fractures in the…
Genetic sequencing and the speed with which it can help diagnose a child’s disease — in addition to revealing the genes that cause at least half of the 7,000 rare diseases currently known — was the focus of a discussion by three top New York geneticists. The Feb. 28 conference,…
Stem Cell-based Therapy Improves Motor Function, Lifespan in Mouse Model of Neuronopathic Gaucher
An experimental, non-invasive stem cell-based therapy led to improved motor function, prolonged lifespan, and reduced neurodegeneration in a mouse model of neuronopathic Gaucher disease (GD), a study shows. The study, “Evaluation of a novel, non-invasive iPSC based cell therapy for neuronopathic Gaucher disease,” was recently presented…
When it comes to rare diseases, one that definitely makes the list is spinal muscular atrophy with respiratory distress — SMARD, for short. Hunter Pageau, a 12-year-old boy from North Haven, Connecticut, is one of only 80 people in the world known to have SMARD, a motor neuron disease…
Recent Posts